Back to search results

Observational Study of Histiocytic Disorders

This study aims to understand more about histiocytic disorders, which are conditions where too many immune cells called histiocytes build up in organs and tissues. Researchers will collect medical and personal histories, as well as samples of blood, other body fluids, or tissue from your disease. The goal is to identify unique features (molecular markers) of these disorders and find potential targets for future treatments. You can join if you are at least 1 year old and have been diagnosed with a histiocytic disorder. This is an observational study, meaning no new treatments are being tested. The study plans to enroll about 500 people. The current status of the study is unclear.

Study design
This is an observational study that plans to include about 500 participants. It is not testing a specific drug or intervention.
What's involved
You will complete questionnaires, provide blood and tissue samples, and your medical records will be reviewed. The duration of these commitments is not specified.
Compensation
Not stated in the trial record.
Follow-up
Changes in PD-L1 and T-cell Bim expression will be measured post-treatment for up to 2 years, potentially 4 times per year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06331377

Clinical and Molecular Characteristics of Histiocytic Disorders

Recruiting
Not specifiedAges 1+Observational
Mayo Clinic
~500 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify molecular markers
Measured over Baseline
+1 more outcome measured

Conditions

Histiocytic Disorder

Explore related trials

Histiocytic Disorder

NCT06331377

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jithma P. Abeykoon, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients diagnosed with histiocytic disorders and age ≥1 year

Exclusion

\< 1 years age

What this trial measures

  • Identify molecular markersBaseline

    Biopsy samples will be analyzed for the presence of molecular markers associated with histiocytic disorders. Potential markers include BRAF V600E, cyclinD1, PD-L1, p16, and p53.6. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.

  • Change in PD-L1 and T-cell Bim expressionBaseline; post-treatment (estimated up to 2 years, potentially 4 times per year)

    Blood testing will be performed for soluble PD-L1 and T-cell Bim expressions before and after radiation therapy for histiocytic disease to assess change in levels and role of immunotherapy. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.